The atrial fibrillation market was valued at USD 17.54 Billion in 2024, driven by the rising technological advancements across the 8 major markets. The market is anticipated to grow at a CAGR of 6.80% during the forecast period of 2025-2034, with the values likely to reach USD 33.86 Billion by 2034.
Base Year
Historical Year
Forecast Year
In November 2024, Johnson & Johnson MedTech gained FDA approval for the Varipulse pulsed field ablation platform. This innovation significantly advances treatment options for patients, thereby, boosting market growth.
The market is experiencing several trends such as rising incidence of minimally invasive procedures, advancing catheter ablation, and incorporating AI for diagnostics.
The United States will likely lead the market driven by its advanced healthcare infrastructure, high levels of awareness, strong research and development efforts, and the increasing prevalence of lifestyle-related diseases, driving demand for advanced treatment solutions in the region.
Atrial fibrillation is an abnormal heart rhythm condition that can result in an irregular and rapid heartbeat, thereby reducing blood flow to the body. It has several risks associated with it, including stroke, heart failure, and other related conditions. Atrial fibrillation occurs when heart's electrical signals become disorganized, thus resulting in uncoordinated atrial contractions. It mostly affects the elderly but can happen at any age. The market growth is driven by an increased prevalence of atrial fibrillation, better treatment options, higher health awareness, and improved diagnostic technology. As a result, there is an increasing demand for both pharmacological and non-pharmacological therapies to manage the condition, with significant market opportunities for innovative treatments and technologies.
Rising Incidence of Atrial Fibrillation to Drive the Market Growth
The increasing prevalence of atrial fibrillation, particularly in the elderly population is a key factor in market growth. According to the Centers for Disease Control and Prevention’s May 2024 data, atrial fibrillation is expected to affect 12.1 million people in the United States by 2030. The high prevalence is increasing due to various lifestyle factors such as high blood pressure, obesity, and diabetes.
Technological Advancements Enhance the Atrial Fibrillation Market Value
Continuous innovation in medical devices and treatment techniques is enhancing the growth of the market. The advancements include the integration of robotic-assisted catheter ablation and advanced pacemakers, enhancing the accuracy and success rate of treatments. These innovations offer better outcomes for patients but also drive market expansion as healthcare providers adopt the latest technologies.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on Treatment Type to Witness Substantial Growth
Based on the type of treatment, the market is segmented into pharmacological treatment and non-pharmacological treatment. Non-pharmacological treatments, especially catheter ablation, are expected to have a significant share in the market. It can be accredited to technological advancements that have improved the safety, success rates, and accessibility of these procedures. As patients look for long-term solutions, non-pharmacological treatments are increasingly preferred, allowing this segment to capture a larger share of the market.
Based on region, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. The market in the United States is driven by a high prevalence of the condition. Moreover, factors such as aging population, advanced treatment, robust health infrastructure, and appropriate reimbursement policies. In the United Kingdom, the market is witnessing growth, driven by increased awareness, better health access, and government support in terms of health and cardiovascular.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
AtriCure was founded in 2000, and it is headquartered in Ohio, USA. The company is a major player in the market and specializes in the development of medical devices for atrial fibrillation treatment.
Boehringer Ingelheim, established in 1885 and based in Ingelheim, Germany, is a global leader in the healthcare industry, especially in heart disease therapies. In the atrial fibrillation market, the company provides Pradaxa (dabigatran), an anticoagulant to prevent stroke in patients. The company is expanding its portfolio with effective therapies for better patient outcomes in atrial fibrillation management.
Boston Scientific is a global leader in medical devices, founded in 1979 and headquartered in Marlborough, Massachusetts. The company offers innovative treatments, including the Watchman Device, designed to reduce stroke risk by closing the left atrial appendage in atrial fibrillation patients. It is committed to advancing heart disease management with cutting-edge technologies for improved patient outcomes.
Bristol Myers Squibb (BMS), founded in 1858 and headquartered in New York, is a global leader in biopharmaceuticals, focusing on areas like cardiovascular diseases. In the atrial fibrillation market, it offers Eliquis (apixaban), an anticoagulant that reduces stroke risk in patients. The company's ongoing research enhances its commitment to providing innovative treatments for better atrial fibrillation management and patient outcomes.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Cardio Focus Inc., Sanofi, Biosense Webster Inc., Abbott, Johnsons & Johnson Services, Inc., and Bayer AG.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share